The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD
| Autor: | Vera Bittner, Emily C. McKinley, Michael E. Farkouh, Stephanie R. Reading, Ligong Chen, Emily B. Levitan, Jason Exter, Monika M. Safford, Lei Huang, Robert S. Rosenson, Kate K. Orroth, Mark Woodward, Lisandro D. Colantonio, Elizabeth A. Jackson, Todd M. Brown, Paul Muntner |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Pharmacology
Ldl cholesterol medicine.medical_specialty education.field_of_study National Health and Nutrition Examination Survey Atherosclerotic cardiovascular disease business.industry Population General Medicine medicine.disease Ezetimibe Internal medicine Attributable risk medicine Pharmacology (medical) Cumulative incidence Cardiology and Cardiovascular Medicine business education Stroke medicine.drug |
| Zdroj: | Cardiovascular Drugs and Therapy. 37:107-116 |
| ISSN: | 1573-7241 0920-3206 |
| DOI: | 10.1007/s10557-021-07268-x |
| Popis: | Adults with atherosclerotic cardiovascular disease (ASCVD) are recommended high-intensity statins, with those at very high risk for recurrent events recommended adding ezetimibe and/or a proprotein convertase subtilisin/kexin type 9 inhibitor if their low-density lipoprotein cholesterol (LDL-C) is ≥70 mg/dL. We estimated the number of recurrent ASCVD events potentially averted if all adults in the United States (US) ≥45 years of age with ASCVD achieved an LDL-C |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink